BMRN
BioMarin Pharmaceutical Inc.
BMRN offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over BMRN overall, supported by stronger modeled upside and stronger valuation.
BMRN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Stable | |
| Weak |
BMRN's revenue is currently strong, and its cash flow is stable, but its profitability and balance sheet are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
BMRN PE Valuation
BMRN has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
BMRN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
BMRN has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
BMRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.46 | — |
| Q3 2026 | -$0.08 | -103% |
| Q2 2026 | $0.39 | -88% |
| Q1 2026 | $1.39 | -49% |
| Q4 2025 | $1.80 | -19% |
| Q3 2025 | $2.67 | +61% |
| Q2 2025 | $3.38 | +156% |
| Q1 2025 | $2.70 | +155% |
| Q4 2024 | $2.21 | +154% |
BMRN has swung to a loss: it lost $0.08 per share over the past year, after a profit the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over BMRN on earnings quality, reporting a profit while its opponent remains loss making.
BMRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +32% |
| Q2 2026 | $989.7M | +20% |
| Q1 2026 | $766.2M | +2.8% |
| Q4 2025 | $874.6M | +17% |
| Q3 2025 | $776.1M | +4.1% |
| Q2 2025 | $825.4M | +16% |
| Q1 2025 | $745.1M | +15% |
| Q4 2024 | $747.3M | +16% |
BMRN has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -8% | -2 points |
| Q2 2026 | 11% | -22 points |
| Q1 2026 | 17% | -13 points |
| Q4 2025 | -5.1% | -27 points |
| Q3 2025 | -6% | -21 points |
| Q2 2025 | 34% | +17 points |
| Q1 2025 | 30% | +16 points |
| Q4 2024 | 22% | +19 points |
BMRN's operating margin was −8% last quarter, down 2 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over BMRN on profitability, with a higher operating margin.
BMRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $159.9M | -53% |
| Q2 2026 | $139.3M | -17% |
| Q1 2026 | $199.7M | +27% |
| Q4 2025 | $58.9M | -65% |
| Q3 2025 | $340.2M | +68% |
| Q2 2025 | $168.2M | +73% |
| Q1 2025 | $157.6M | +655% |
| Q4 2024 | $166.1M | +$167.5M |
BMRN still generates free cash flow, though less than at its 2025 peak: $558M over the past year.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
BMRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -877K shares |
| 1 year | +0.8% | +1.6M shares |
| 3 years | +1.3% | +2.4M shares |
| 5 years | +5.7% | +10.4M shares |
| Available history | +8.1% | +14.6M shares |
BMRN has 194M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over BMRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
BMRN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 9.1x | High |
| Q2 2026 | 11.0x | High |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -2.7x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.6x | Net Cash |
BMRN's net debt is about 9.1 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH has the edge over BMRN on leverage, with a lower net debt burden relative to earnings.
BMRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.3 | Neutral |
| Stochastic | 24.3 | Neutral |
BMRN's weekly RSI is 45 (neutral) and its Stochastic is 24 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
BMRN PE vs Healthcare Sector
| Metric | BMRN | Sector median | Relative |
|---|---|---|---|
| PE | 150x | 26x | 480% above |
| PE % | 67 | 29 | 38 pts above |
BMRN has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over BMRN on valuation relative to its sector.
BMRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $56.8 | 0.1% below |
| 20 week MA | $60.5 | 6.3% below |
| 50 week MA | $58.2 | 2.6% below |
| 100 week MA | $59.0 | 3.9% below |
| 200 week MA | $73.1 | 22% below |
BMRN is in a downtrend: it's below all five of its weekly moving averages, and 22% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over BMRN on trend strength, trading above more of its moving averages.
BMRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $85.6 | $88.7 | +3.6% |
| 2021 | $88.7 | $91.2 | +2.8% |
| 2022 | $91.2 | $104.3 | +14% |
| 2023 | $104.3 | $96.4 | -7.6% |
| 2024 | $96.4 | $66.9 | -31% |
| 2025 | $66.9 | $60.0 | -10% |
| 2026 YTD | $60.0 | $56.7 | -5.4% |
BMRN has finished three years in a row lower, and it's down 5.4% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over BMRN on returns for 2026, with the stronger performance.